Millie
your market intelligence analyst
Search Results
367 results
Your search is now limited to «GLP-1 Agonist» expert search.
FeedNavigator (EU) 10/13/2019 00:02
BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject areas.
More from FeedNavigator (EU):
Healio News 10/12/2019 11:28
Insulin remains a critical medication in the treatment of type 2 diabetes, although its role is different than it was prior to the introduction of SGLT2 inhibitors and GLP-1 receptor agonists,” Irl B. Hirsch, MD, professor of medicine at the University of Washington in Seattle, said during a presentation.
More from Healio News:
ClinicalTrials.gov 10/10/2019 08:47
Condition : Obesity Interventions : Drug: Liraglutide; Behavioral: Exercise Sponsors : Signe Torekov; Hvidovre University Hospital; University of Oxford; Karolinska Institutet Active, not recruiting.
More from ClinicalTrials.gov:
PR Newswire 10/08/2019 08:01
BOSTON, Oct. 8, 2019 /PRNewswire/ -- Intarcia Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its new drug application (NDA) for ITCA 650 (exenatide implant), for the treatment of type 2 diabetes mellitus....
More from PR Newswire:
Medical Xpress 10/07/2019 14:00
Black and ethnic minority people are not as likely to be prescribed newer medication for Type 2 diabetes and they experience less adequate monitoring of their condition compared to their white peers, new collaborative research from the University of Surrey and Eli Lilly and Company Limited finds.
More from Medical Xpress:
Business Wire 10/07/2019 11:45
In this trial, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor, biguanide, sulphonylurea, glinide, alpha-glucosidase inhibitor, thiazolidine and GLP1 receptor agonist.
More from Business Wire:
Cardiovascular Diabetology 10/04/2019 20:00
Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss.
More from Cardiovascular Diabetology:
Lancet 10/03/2019 19:16
The main goal of treatment for type 1 diabetes is to control glycaemia with insulin therapy to reduce disease complications. For some patients, technological approaches to insulin delivery are inadequate, and allogeneic islet transplantation is a safe alternative for those patients who have had severe hypoglycaemia complicated by impaired hypoglycaemia awareness or glycaemic lability, or who already receive immunosuppressive drugs for a kidney transplant. Since 2000, intrahepatic islet transplantation has proven efficacious in alleviating the burden of labile diabetes and preventing complications related to diabetes, whether or not a previous kidney transplant is present.
More from Lancet:
American Diabetes Journals 10/02/2019 10:49
Obesity is taking worldwide epidemic proportions, yet effective pharmacological agents with long-term efficacy remain unavailable. Previously, we designed the iminosugar AMP-DNM which potently improves glucose homeostasis by lowering excessive glycosphingolipids. Here we show that AMP-DNM promotes satiety and activates brown adipose tissue (BAT) in obese rodents. Moreover, we demonstrate that the mechanism mediating these favorable actions depends on oral, but not central, administration of AMP-DNM, which ultimately stimulates systemic glucagon-like peptide-1 (GLP1) secretion. We evidence an essential role of brain GLP1 receptors (GLP1r) as AMP-DNM fails to promote satiety and activate BAT in mice lacking the brain GLP1r as well as in mice
More from American Diabetes Journals:
BioPharma Dive 10/01/2019 15:12
While the drugmaker has advanced a long-acting GLP-1 agonist, Sanofi trails Novo and Lilly in diabetes drug markets outside of insulin.
More from BioPharma Dive:
GlobeNewswire 09/30/2019 16:45
GENFIT: H1 2019 RESULTS AND R&D PIPELINE PROGRESSION.
More from GlobeNewswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications